Stem Cell-Based Therapeutic Delivery: Challenges & Opportunities


Full Paper

Interactive Report

Price: £150.00
Description: This INTERACTIVE report provides a detailed analysis of key player and technologies under development to improve the delivery of emerging stem cell-based therapies.

More information on Interactive Reports (opens in new tab)

Full Paper

Full Paper

Price: £150.00
Description: This report provides a detailed analysis of key player and technologies under development to improve the delivery of emerging stem cell-based therapies.

Full Paper

Executive Summary

Price: £15.00
Description: This is a precisé of the key findings of companies and technologies under development to improve the delivery of emerging stem cell-based therapies.

Full Paper

PowerPoint Presentation

Price: £50.00
Description: A powerpoint presentation of 21 tables included in the full report; with relevant annotations.

Research Report Overview

Published Date: 15/12/2008
Category: Drug Delivery & Devices

Research Report Decription

pdf icon

Sample Pages:

Click here (PDF)

This report gives in depth analysis of innovative drug delivery technologies that are being applied to both innovative cancer therapies and those that are currently in use. Innovative parenteral, oral and transdermal delivery technologies are considered in the report and forecasts given of the sales of products incorporating these technologies.

Key Questions Answered:

  • Which companies & academic institutes are actively involved in stem cell therapy research?
  • What are the key areas of therapeutic focus for stem cell therapeutics in the near & long-term?
  • What are the key obstacles companies & delivery technologists need to overcome to commercialize stem cell-derived therapies?
  • How will the delivery technology drive the development of innovative stem cell-derived therapies in the future?
  • Which stem cell technologies & agents are likely to win in the near-term & long-term, & why?
  • Where are the market opportunities now & in the future?
  • When are stem cell-derived medicines likely to reach the market?
  • What do we predict will be the value of the stem-cell derived therapeutics by 2015 & 2020?

Companies Mentioned:

Aastrom Biosciences, Advanced Cell technology, Aldagen, Amorcyte Inc, Angioblast, Arteriocyte Inc, AstraZeneca, Athersys, Baxter Healthcare, Beike Biotechnology, BioE, Bioheart, BrainStorm Cell Therapeutics, California Stem Cell Inc, Cardio3 BioSciences, CDI, Celegos, Celgene Cellular Therapeutics, Cell Cure Neurosciences, Cellartis, CellCyte Genetics, Cellerant Therapeutics, Cellerix, Cytori Therapeutics, EndGenitor Technologies Inc, Gamida Cell, Genzyme, Geron Corporation, GlaxoSmithKline, MaxCyte, MedCell, Neuralstem Inc, NeuroGeneration, Neuronyx, Northern Therapeutics, Novartis, Novo Nordisk, Novocell, Opexa Therapeutics, Osiris Therapeutics, Pfizer, Plureon, Pluristem Therapeutics Inc, Q Therapeutics Inc, Regenetech Inc, Reliance Life Sciences, ReNeuron, RhinoCyte, Roche, Saneron CCEL Therapeutics Inc, StemCells Inc, Stemedica, Stemnion, Teva Pharmaceuticals, Theradigm, TheraVitae, Vesta Therapeutics, ViaCord

Paper Highlights:

  • Stem cells have grabbed the attention of scientists across the globe and the pace of research has been astonishing. It is just 10 years since the first human embryonic stem cells (hESCs) were isolated and cultured; new therapies based on this research are now reaching the clinical phase of testing.
  • Many challenges have faced those aiming to develop therapies derived from stem cells including: ethical debates and funding, immune rejection, cancerous potential and issues surrounding the manufacture of stable, pure cell therapeutics.
  • It is evidence of the growing maturity of the field that many potential products have overcome these hurdles and have entered clinical testing.
  • Our research has revealed a total of 122 stem cell-derived therapeutic projects being undertaken in companies across the globe. The majority of these projects are in the earliest stages (28%) or in preclinical studies (43%). Of the projects that have reached clinical trials, only a handful have passed initial Phase 1/2 testing, with a total of eight (7%) being investigated in Phase 3 studies.
  • The market for stem cell therapeutics is forecast to grow from 2011, as the first products enter the marketplace, and is expected to generate global sales in excess of US$1.2 billion by 2015.
  • Autologous products, derived from a patient’s own tissue, will be the first to reach the market, but ‘off-the-shelf’ allogeneic products may offer greater commercial potential. The first allogeneic product to achieve approval is likely to be Osiris Therapeutics’ Prochymal for graft versus host disease.
  • Delivery of stem cell-based therapeutics can be challenging. Osiris’ Prochymal is unique among those reviewed, as it is delivered intravenously, offering obvious commercial advantages. Other therapies are being delivered directly to the site of injury, involving state-of-the-art catheters and imaging systems. The delivery of stem cells for CNS disorders remains a challenging area.